Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Demonstration--Cooperative Agreements (U18)
Project #
5U18FD004004-03
Application #
8535545
Study Section
Special Emphasis Panel (ZFD1-SRC (99))
Project Start
2010-09-17
Project End
2013-09-16
Budget Start
2012-09-17
Budget End
2013-09-16
Support Year
3
Fiscal Year
2012
Total Cost
Indirect Cost
Name
Global Alliance for Tb Drug Development
Department
Type
DUNS #
103139841
City
New York
State
NY
Country
United States
Zip Code
10005
Ordonez, Alvaro A; Tasneen, Rokeya; Pokkali, Supriya et al. (2016) Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. Dis Model Mech 9:779-88
Li, Si-Yang; Irwin, Scott M; Converse, Paul J et al. (2015) Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother 59:4026-30
Dutta, Noton K; Alsultan, Abdullah; Gniadek, Thomas J et al. (2013) Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother 57:3910-6
Dutta, Noton K; Alsultan, Abdullah; Peloquin, Charles A et al. (2013) Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. Antimicrob Agents Chemother 57:1535-7
Dutta, Noton K; Illei, Peter B; Peloquin, Charles A et al. (2012) Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother 56:3726-31
Rosenthal, Ian M; Tasneen, Rokeya; Peloquin, Charles A et al. (2012) Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 56:4331-40